Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Operating income | -$9.37M | -$136M | -$250M | $16.1M | -$6.76M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| Net income | $9.77M | -$144M | -$259M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.60M | -$13.2M | -$28.4M |
| EPS (diluted) | $119.91 | -$8.60 | -$5.16 | -$0.01 | -$6.45 | -$2.06 | -$19.66 | -$5.64 | -$6.94 | -$6.68 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.93M | -$5.43M | -$10.7M | -$3.66M | -$7.26M | -$15.6M | -$15.2M | -$8.85M | -$12.9M | -$12.9M |
| Capital expenditures | $0.00 | $4.00K | $36.0K | $0.00 | — | — | — | — | — | — |
| Free cash flow | -$1.93M | -$5.43M | -$10.7M | -$3.66M | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | $229K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.0K | $576K | $60.0K | $28.0K | $5.30M | $8.97M | $5.67M | $1.08M | $3.95M | $6.81M |
| Total assets | $25.0K | $254M | $25.4M | $396K | $5.66M | $32.2M | $16.7M | $14.1M | $4.23M | $7.12M |
| Total liabilities | $18.9M | $2.68M | $14.0M | $19.7M | — | $10.3M | $5.00M | $6.63M | — | $31.0M |
| Shareholders' equity | -$18.9M | $252M | $11.4M | -$19.3M | -$29.4M | $21.9M | $11.7M | $7.48M | -$1.67M | -$25.9M |
| Retained earnings | -$125M | -$269M | -$529M | -$567M | -$596M | -$654M | -$674M | -$682M | -$695M | -$726M |
| Shares (wtd avg diluted) | 81.5B | 16.8B | 50.2B | 3.38M | 4.39M | 28.2M | 1.06M | 1.35M | 1.90M | 5.51M |
Every figure is extracted from GT Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.